Cargando…
Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea
INTRODUCTION: South Korea regards tuberculosis (TB) incidence in congregate settings as a serious problem. To this end, systematic latent TB infection (LTBI) diagnosis and treatment were provided to approximately 1.2 million individuals in high-risk congregate settings. METHODS AND ANALYSIS: We desi...
Autores principales: | Min, Jinsoo, Kim, Hyung Woo, Stagg, Helen R, Lipman, Marc, Rangaka, Molebogeng X, Myong, Jun-Pyo, Yim, Hyeon Woo, Lim, Jeong Uk, Lee, Yunhee, Koo, Hyeon-Kyoung, Lee, Sung-Soon, Park, Jae Seuk, Cho, Kyung Sook, Kim, Ju Sang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045012/ https://www.ncbi.nlm.nih.gov/pubmed/32075836 http://dx.doi.org/10.1136/bmjopen-2019-034098 |
Ejemplares similares
-
Latent Tuberculosis Infection Screening and Treatment in Congregate Settings (TB FREE COREA): Demographic Profiles of Interferon-Gamma Release Assay Cohort
por: Kim, Hyung Woo, et al.
Publicado: (2021) -
The cascade of care for latent tuberculosis infection in congregate settings: A national cohort analysis, Korea, 2017–2018
por: Min, Jinsoo, et al.
Publicado: (2022) -
Latent Tuberculosis Cascade of Care Among Healthcare Workers: A Nationwide Cohort Analysis in Korea Between 2017 and 2018
por: Min, Jinsoo, et al.
Publicado: (2022) -
Prevalence of latent tuberculosis infection among participants of the national LTBI screening program in South Korea – A problem of low coverage rate with current LTBI strategy
por: Kim, Hyung Woo, et al.
Publicado: (2023) -
Evaluating the effect of short-course rifapentine-based regimens with or without enhanced behaviour-targeted treatment support on adherence and completion of treatment for latent tuberculosis infection among adults in the UK (RID-TB: Treat): protocol for an open-label, multicentre, randomised controlled trial
por: Rangaka, Molebogeng X, et al.
Publicado: (2022)